Fuzhou Children's Hospital of Fujian Province, Fujian, China.
Medicine (Baltimore). 2023 Jun 9;102(23):e33998. doi: 10.1097/MD.0000000000033998.
Oral propranolol has not been shown to impact physical development, such as weight and height. The impact of children's intellectual development has received relatively little attention from researchers. The effects of propranolol on the growth and development of children with proliferative infantile hemangiomas during treatment were analyzed retrospectively. The children with infantile hemangioma treated with oral propranolol in the Department of Burn and Plastic Surgery, Fuzhou Children's Hospital of Fujian Province, from February 2017 to May 2022 were analyzed. A uniform therapeutic regimen was applied, including assessment, treatment, and follow-up. The assessment included physical development and intellectual development indices. The physical development indices were height and weight. Neuropsychological assessment uses developmental quotient (DQ) to assess intelligence development. The DQs on months 3, 6, and 9 posttreatment were compared to the pretreatment. Wilcoxon rank sum test of paired samples was used for height and weight. The developmental quotient was determined by paired t test. P < .05 indicated significant difference. A total of 51 patients were enrolled. All children completed the treatment successfully, without severe adverse drug reactions leading to treatment discontinuation. There was no significant difference in height and weight before and after treatment (P > .05). No significant difference was detected in DQ 3 months posttreatment and pretreatment (P = .19), while it decreased at 6 and 9 months posttreatment (P < .05). Oral propranolol does not have an impact on physical development (height and weight). No short-term effect was found on intellectual development, but a decrease was noted over 6 months, which needs to be investigated further.
口服普萘洛尔尚未显示会影响身体发育，如体重和身高。儿童智力发育的影响受到研究人员的关注相对较少。回顾性分析了口服普萘洛尔治疗增殖性婴儿血管瘤患儿的生长发育情况。分析了 2017 年 2 月至 2022 年 5 月在福建省福州儿童医院烧伤整形科接受口服普萘洛尔治疗的婴儿血管瘤患儿。采用统一的治疗方案，包括评估、治疗和随访。评估包括身体发育和智力发育指标。身体发育指标为身高和体重。神经心理学评估使用发育商（DQ）评估智力发育。比较治疗后 3、6 和 9 个月的 DQ 与治疗前的 DQ。采用配对样本 Wilcoxon 秩和检验进行身高和体重的比较，采用配对 t 检验确定发育商。P<0.05 表示差异有统计学意义。共纳入 51 例患儿。所有患儿均顺利完成治疗，无严重药物不良反应导致治疗中断。治疗前后身高和体重无显著差异（P>0.05）。治疗后 3 个月 DQ 与治疗前无显著差异（P=0.19），但治疗后 6 个月和 9 个月时 DQ 下降（P<0.05）。口服普萘洛尔对身体发育（身高和体重）没有影响。智力发育方面未发现短期影响，但 6 个月后出现下降，需要进一步研究。
